Skip to main content

Zealand Pharma

Zealand Pharma A/S is a biotechnology company focused on the discovery, design, and development of innovative peptide-based medicines for metabolic and gastrointestinal diseases. The company operates through research and clinical development segments dedicated to creating novel therapeutics addressing obesity, diabetes, and rare disorders. Its principal revenue drivers stem from milestone payments, research collaborations, and commercial license agreements established with major pharmaceutical partners, alongside future drug commercialization prospects. The firm maintains a significant international scale and a specialized market position within peptide drug discovery and metabolic healthcare innovation, collaborating with global industry leaders. By advancing proprietary therapeutic candidates through rigorous clinical trials, the enterprise addresses critical unmet medical needs. Zealand Pharma is officially headquartered in Søborg, Denmark, and its ordinary shares are publicly listed and traded on Nasdaq Copenhagen.

26 of the funds FundTelligence covers report a position in Zealand Pharma.

Legal name
Zealand Pharma AS
Sector
Health Care
Country
Denmark
Funds holding it
26
Exposure themes
Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health

Funds holding Zealand Pharma

Showing the 8 largest of 26 funds holding it.

Loading...